| Market Capitalization (Millions $) |
1,235 |
| Shares
Outstanding (Millions) |
92 |
| Employees |
21 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-134 |
| Cash Flow (TTM) (Millions $) |
-44 |
| Capital Exp. (TTM) (Millions $) |
2 |
Edgewise Therapeutics Inc
Edgewise Therapeutics is a pharmaceutical company that is focused on the development of muscle-specific drugs. The company has a platform technology that allows it to create drugs that target specific muscles, which can help address debilitating diseases and conditions that affect the musculature system.
The companyes lead drug candidate is called EDG-5506, which is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). DMD is a genetic disorder that causes muscle degeneration and weakness, affecting around 1 in every 3,500 boys worldwide. There is currently no cure for the disease, and existing treatments only help manage the symptoms.
EDG-5506 works by inhibiting the activity of enzymes that are responsible for breaking down and degrading a protein called dystrophin, which is crucial for healthy muscle function. By blocking these enzymes, the drug can increase the production and availability of dystrophin, which can help improve muscle strength and function in patients with DMD.
In addition to its lead program in DMD, Edgewise Therapeutics is also working on developing drugs for other muscle-specific disorders, including facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophy (LGMD), and Becker muscular dystrophy (BMD). The companyes platform technology allows it to target these specific muscles with precision, which can increase the efficacy and safety of its drugs.
Edgewise Therapeutics was founded in 2017 and is headquartered in Boulder, Colorado. The company has raised over $127 million in funding to date, including a $95 million Series B funding round in 2020 led by Sofinnova Investments and RA Capital Management. The companyes management team includes experienced industry veterans with backgrounds in drug development, clinical research, and business development.
Company Address: 1715 38th St. Boulder 80301 CO
Company Phone Number: 262-7002 Stock Exchange / Ticker: NASDAQ EWTX
|
3.78%